Every Form 4 that SBC Medical Group Holdings Incorporated (SBC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SBC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBC filings page.
SBC Medical Group Holdings Inc Chairman and CEO Yoshiyuki Aikawa reported an open-market sale of 465,000 shares of common stock on April 28, 2026 at a net price of $3.0225 per share. The sale occurred on the closing date of the underwriters' option to purchase additional shares tied to an underwritten public offering that initially closed on April 21, 2026.
Following the transaction, Aikawa holds 78,839,460 SBC shares directly, plus indirect interests including 5,000,000 shares held by Aikawa Investment Co., Ltd., which he wholly owns, and an 861,600-share indirect interest through Aikawa Equity Management Co., Ltd., where he disclaims beneficial ownership except for his pecuniary interest.
SBC Medical Group Holdings Inc Chairman and CEO Yoshiyuki Aikawa sold 3,100,000 shares of common stock at a net price of $3.0225 per share in an underwritten public offering that closed on April 21, 2026.
Following the sale, he holds 79,304,460 SBC shares directly, plus 5,000,000 shares indirectly through Aikawa Investment Co., Ltd., a company he wholly owns. He also reports an indirect interest corresponding to 861,600 shares held by Aikawa Equity Management Co., Ltd., while disclaiming beneficial ownership beyond his pecuniary interest.
SBC Medical Group Holdings Inc’s Form 4 shows a complex restructuring by Chairman and CEO Yoshiyuki Aikawa involving entities that hold the company’s common stock. An affiliated company, Aikawa Equity Management Co., Ltd. (AEM), directly holds 5,284,500 SBC shares, with each AEM share corresponding to one hundred SBC shares.
The filing reports open‑market sales of 4,422,900 SBC shares at $2.12 per share, but a footnote clarifies that no actual SBC shares were sold. Instead, Aikawa sold AEM shares under separate purchase agreements to consultants tied to medical corporations working with SBC subsidiaries, and the numbers shown reflect the SBC shares corresponding to AEM shares sold.
Following these transactions, Aikawa no longer controls AEM and disclaims beneficial ownership of the SBC shares held by AEM, except for his pecuniary interest. He is deemed to have indirect beneficial ownership of 861,600 SBC shares through AEM, and continues to hold additional SBC shares directly and indirectly through another entity, GODO Kaisha Aikawa Investment.